Literature DB >> 3947866

Carotid body tumour: 30 years experience.

P H Dickinson, S M Griffin, A J Guy, I F McNeill.   

Abstract

Thirty-two patients with 37 carotid body tumours, seen in the Vascular Unit at the Royal Victoria Infirmary, Newcastle upon Tyne between 1956 and 1985 are reviewed. Twenty-six of the tumours were treated by surgical excision. There were no peri- or postoperative deaths, but one patient developed a permanent hemiplegia following surgery (3.8 per cent); cranial nerve palsy occurred in five patients (19.2 per cent). There were no malignant tumours although in one patient, histology of the resected specimen showed the presence of local lymph node invasion (3.8 per cent). In the 7 patients who did not undergo surgery, 3 have been lost to follow-up; the remainder have not shown any significant increase in the size of the tumour. One patient was treated by radiotherapy. It is concluded that surgical excision is the treatment of choice, though observation may be preferred for the older patient with a symptomless, slow-growing tumour. To help reduce the risk of hemiplegia (the most serious complication of surgery) a meticulous surgical technique is necessary and heparin, intraluminal shunting and facilities for arterial repair and grafting must be at hand.

Entities:  

Mesh:

Year:  1986        PMID: 3947866     DOI: 10.1002/bjs.1800730107

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  13 in total

1.  Carotid body tumors at high altitudes: Quito, Ecuador, 1987.

Authors:  L Pacheco-Ojeda; E Durango; C Rodriquez; N Vivar
Journal:  World J Surg       Date:  1988-12       Impact factor: 3.352

2.  Cervical paragangliomas: neurovascular surgical risk and therapeutic management.

Authors:  J Paris; F Facon; J M Thomassin; M Zanaret
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-07-06       Impact factor: 2.503

3.  Risk factors for stroke during surgery for carotid body tumors.

Authors:  Jun Gyo Gwon; Tae-Won Kwon; Hyangkyoung Kim; Yong-Pil Cho
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

4.  Carotid body paragangliomas: a systematic study on management with surgery and radiotherapy.

Authors:  Carlos Suárez; Juan P Rodrigo; William M Mendenhall; Marc Hamoir; Carl E Silver; Vincent Grégoire; Primož Strojan; Hartmut P H Neumann; Rupert Obholzer; Christian Offergeld; Johannes A Langendijk; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-02-19       Impact factor: 2.503

5.  Phaeochromocytoma--investigation and management of 10 cases.

Authors:  J E Deal; P S Sever; T M Barratt; M J Dillon
Journal:  Arch Dis Child       Date:  1990-03       Impact factor: 3.791

6.  Late outcome after surgical management of carotid body tumors from a 20-year single-center experience.

Authors:  Drosos Kotelis; Timolaos Rizos; Philipp Geisbüsch; Nicolas Attigah; Peter Ringleb; Werner Hacke; Jens-Rainer Allenberg; Dittmar Böckler
Journal:  Langenbecks Arch Surg       Date:  2008-07-17       Impact factor: 3.445

7.  Synchronous malignant vagal paraganglioma with contralateral carotid body paraganglioma treated by radiation therapy.

Authors:  Tejinder Kataria; Shyam Singh Bisht; Swarupa Mitra; Ashu Abhishek; Suryaprakash Potharaju; Devlina Chakarvarty
Journal:  Rare Tumors       Date:  2010-06-30

8.  Hepatic metastatic paraganglioma 12 years after retroperitoneal paraganglioma resection: a case report.

Authors:  Zhao-Ru Dong; Yan-Ni Xia; Yue-Yi Zhao; Rui Wu; Kai-Xuan Liu; Kai Shi; Lun-Jie Yan; Cheng-Yu Yao; Yu-Chuan Yan; Tao Li
Journal:  BMC Gastroenterol       Date:  2019-08-08       Impact factor: 3.067

9.  A 22-year Northern Irish experience of carotid body tumours.

Authors:  Stephen O'Neill; Mark O'Donnell; Denis Harkin; Maurice Loughrey; Bernard Lee; Paul Blair
Journal:  Ulster Med J       Date:  2011-09

10.  Collet-Sicard syndrome secondary to a large glomus jugulotympanicum.

Authors:  Saifullah Khalid; Samreen Zaheer; Mohd Khalid; Sufian Zaheer; Raj Kumar Raghuwanshi
Journal:  Ann Saudi Med       Date:  2013 Jul-Aug       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.